Gastroenterology – Page 2

Optimizing Encapsulated Faecal Microbiota Transplantation for Clostridioides difficile Infection: Empirical Donor Selection and Two-Dose Regimen Enhance Cure Rates

By MedXY 10/09/2025

This study demonstrates that empirical donor exclusion combined with a two-dose capsule regimen significantly improves cure rates in Clostridioides difficile infection treated with encapsulated faecal microbiota transplantation (FMT).

Gastroenterology news Public Health

Opioid Use in Rome IV Irritable Bowel Syndrome: Prevalence and Impact on Quality of Life and Healthcare in the UK

By MedXY 10/09/2025

One in five UK patients with Rome IV IBS regularly use opioids, associated with worse quality of life, more psychological distress, and increased healthcare costs, highlighting a critical need for opioid stewardship in IBS management.

Diabetes & Endocrinology Gastroenterology news

Noninvasive Biomarkers Track Semaglutide Efficacy in Metabolic Dysfunction-Associated Steatohepatitis

By MedXY 10/09/2025

A phase 2b trial demonstrates that several noninvasive tests reliably reflect treatment response to semaglutide in patients with metabolic dysfunction-associated steatohepatitis, correlating with histologic improvements over 72 weeks.

Gastroenterology news

Gut Microbiota as a Key Determinant of Quality of Life Impairment in Inflammatory Bowel Disease

By MedXY 10/09/2025

A recent cross-sectional study reveals that alterations in gut microbiota correlate more strongly with impaired health-related quality of life in IBD patients than clinical disease activity, suggesting novel microbial therapeutic targets beyond immunosuppression.

Gastroenterology news Pediatrics

FDA Approves Golimumab (Simponi) for Pediatric Ulcerative Colitis: A New Therapeutic Option

By MedXY 10/08/2025

The FDA has approved golimumab (Simponi) for treating moderately to severely active ulcerative colitis in children weighing at least 15 kg, based on the PURSUIT 2 phase 3 study demonstrating significant clinical remission and safety.

Gastroenterology news Oncology

Menopausal Hormone Therapy and Reduced Risk of Upper Gastrointestinal Cancers: Insights From a Large Nordic Population Study

By MedXY 10/08/2025

A large Nordic study finds menopausal hormone therapy reduces the risk of esophageal and gastric cancers by up to 30%, especially with combined estrogen-progestin systemic formulations.

Gastroenterology Infectious Diseases news Pediatrics

Revisiting Rehydration Strategies in Severe Acute Malnutrition with Gastroenteritis: Intravenous Versus Oral Approaches

By MedXY 10/03/2025

A recent trial assessing intravenous versus oral rehydration in children with severe acute malnutrition and gastroenteritis found no mortality difference at 96 hours, challenging fears of fluid overload and supporting cautious consideration of intravenous therapy.

Gastroenterology news Specialties

Primary Sclerosing Cholangitis in a 45-Year-Old Male: A Case Report

By MedXY 10/02/2025

A 45-year-old male presents with cholestatic liver enzyme elevation and pruritus, diagnosed with primary sclerosing cholangitis confirmed by imaging and liver biopsy. Clinical management and prognosis are discussed.

Gastroenterology news

Cendakimab: A Promising Therapeutic for Eosinophilic Esophagitis in Adolescents and Adults

By MedXY 09/26/2025

Cendakimab, a monoclonal antibody targeting IL-13, shows significant improvements in symptoms, histologic response, and endoscopic features in eosinophilic esophagitis, with a tolerable safety profile through 48 weeks.

Clinical Updates Gastroenterology news

Decoding the Role of Reflux Secondary Bile Acids in Barrett’s Esophagus: Microbiome and Transcriptome Insights

By MedXY 09/25/2025

This study reveals that elevated reflux secondary bile acids in Barrett's esophagus influence the esophageal microbiome and gene expression, highlighting potential mechanisms underpinning progression to esophageal adenocarcinoma.

Gastroenterology news Specialties

The Withdrawal of OCALIVA: Impact and Implications for Primary Biliary Cholangitis Treatment

By MedXY 09/21/2025

Intercept Pharmaceuticals withdraws OCALIVA from the US market following FDA demands due to safety concerns and lack of proven efficacy in PBC, prompting suspension of related clinical trials and significant shifts in therapeutic landscape.

AI Clinical Updates Gastroenterology Internal Medicine news Pathology & Lab Medicine

Enhancing Fibrosis Scoring in MASH: The Role of AI-Enhanced Digital Pathology

By MedXY 09/20/2025

AI-assisted digital pathology improves inter-pathologist agreement on fibrosis staging in metabolic dysfunction-associated steatohepatitis (MASH), enhancing clinical trial accuracy and efficiency.

Clinical Updates Gastroenterology Internal Medicine news Specialties

HEC88473 Dual GLP-1/FGF21 Agonist: Advancing Treatment for MASLD and T2DM with Promising Safety and Efficacy

By MedXY 09/20/2025

A phase Ib/IIa trial demonstrated that HEC88473, a novel GLP-1/FGF21 dual agonist, is generally safe, effectively reduces liver fat, and improves glycemic and lipid profiles in MASLD patients with type 2 diabetes within five weeks of treatment.

Clinical Updates Gastroenterology Internal Medicine news

AZD2693: Targeting PNPLA3 148M Variant as a Precision Therapy for Metabolic Steatohepatitis

By MedXY 09/20/2025

AZD2693, a liver-directed antisense oligonucleotide, safely reduces PNPLA3 expression and liver fat in homozygous PNPLA3 148M carriers with metabolic dysfunction-associated steatohepatitis, signaling promise for precision treatment in this genetically defined subgroup.

Clinical Updates Gastroenterology Internal Medicine news

Rapirosiran: A Promising RNAi Therapy Targeting HSD17B13 in Metabolic Dysfunction-Associated Steatohepatitis

By MedXY 09/20/2025

This phase I study evaluates rapirosiran, an RNA interference therapeutic targeting HSD17B13, demonstrating safety, tolerability, and significant liver mRNA reduction in patients with metabolic dysfunction-associated steatohepatitis (MASH).

Clinical Updates Gastroenterology news Transplantation

The THEMATIC Trial: Advancing Microbiota Transplantation to Prevent Hepatic Encephalopathy Recurrence in Cirrhosis

By MedXY 09/20/2025

The THEMATIC phase II trial demonstrates that fecal microbiota transplantation (FMT) is safe and reduces HE recurrence in cirrhosis, independent of dose, route, or donor diet, with gut microbiota engraftment linked to clinical outcomes.

Clinical Updates Gastroenterology Internal Medicine news Specialties

Pan-PPAR Agonist Lanifibranor: A Breakthrough in Improving Insulin Resistance and Hepatic Steatosis in T2D and MASLD Patients

By MedXY 09/20/2025

Lanifibranor, a pan-PPAR agonist, significantly reduces liver fat and improves insulin sensitivity at multiple tissue sites in type 2 diabetes patients with MASLD, offering a new therapeutic avenue to address underlying metabolic dysfunction.

Clinical Updates Gastroenterology Internal Medicine news

Icosabutate in Metabolic Dysfunction-Associated Steatohepatitis: Insights from the Phase IIb ICONA Trial

By MedXY 09/20/2025

A phase IIb trial of the FFAR1/FFAR4 agonist icosabutate in MASH shows encouraging fibrosis improvement and biomarker responses despite not meeting the primary endpoint, supporting further development.

Clinical Updates Gastroenterology Internal Medicine news Specialties

Icosabutate and FFAR1/FFAR4 Agonism in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Insights from the ICONA Phase IIb Trial

By MedXY 09/20/2025

The phase IIb ICONA trial evaluated icosabutate, a dual FFAR1/FFAR4 agonist, in patients with MASH, showing fibrosis improvement without meeting the primary endpoint, and supporting further development particularly in advanced fibrosis and diabetic populations.

Family Medicine & Nutrition Gastroenterology news Specialties

Why Losing Weight Can Worsen Fatty Liver Disease: The Crucial Role of Balanced Nutrition

By MedXY 09/18/2025

Losing weight doesn't always mean improving fatty liver disease. Discover why strict diets lacking essential proteins can worsen liver health and learn practical dietary strategies to manage and reverse fatty liver effectively.